antibody

POLR2A (Ab-1619) Antibody

MBS8502228

0.1 mg

280 USD

polyclonal

rabbit

nonconjugated

human, mouse, rat

western blot, ELISA, immunohistochemistry, immunocytochemistry, enzyme immunoassay

Antibody

POLR2A (Ab-1619) Antibody

[POLR2A]

[RPO2; RPOL2; POLR2 ALPHA-AMANITIN RESISTANCE; POLYMERASE II RNA; SUBUNIT A; RNA POLYMERASE II; 220-KD SUBUNIT; RNA POLYMERASE II; LARGE SUBUNIT; RPB1; S. CEREVISIAE; HOMOLOG OF polymerase (RNA) II (DNA directed) polypeptide A]

[DNA-directed RNA polymerase II subunit RPB1; DNA-directed RNA polymerase II subunit RPB1; DNA-directed RNA polymerase II subunit RPB1; RNA polymerase II subunit A; DNA-directed RNA polymerase II subunit A; DNA-directed RNA polymerase III largest subunit; RNA-directed RNA polymerase II subunit RPB1 (EC:2.7.7.48)]

[POLR2A]

[POLR2A; POLR2A; RPB1; RPO2; POLR2; POLRA; RPBh1; RPOL2; RpIILS; hsRPB1; hRPB220; POLR2; RNA polymerase II subunit B1]

polyclonal

IgG

rabbit

Human, Mouse, Rat

1970

POLR2A (Ab-1619) antibody detects endogenous levels of total POLR2A protein.

Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

In phosphate buffered saline (without Mg 2+ and Ca 2+ ), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Store at-20 degree C for 1 year

Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), ELISA (EIA)

WB: 1:500~1:1000. IHC: 1:50~1:100. IF: 1:100~1:500. ELISA: 1:10000

Immunohistochemistry (IHC)

Western Blot (WB)

Immunofluorescence (IF)

Immunogen: The antiserum was produced against synthesized non-phosphopeptide derived from human POLR2A around the phosphorylation site of serine 1619 (P-T-S-P-S).

Autophagy antibody; Cancer; Cardiovascular; Cell Biology; Epigenetics & Nuclear Signaling; Developmental Biologys; Immunology; Drug Discovery Products; Metabolism; Neuroscience; Signal Transduction; Stem Cells

Tracy Jo Pasieka, J. Virol., Aug 2006; 80: 7600-7612. Olaf R. Mook, Mol. Cancer Ther., Mar 2007; 6: 833-843. Colleen A. McMullen, J. Neurosci., Jan 2004; 24: 161.

4505939

NP_000928.1

NM_000937.4

P24928

Abortive Elongation Of HIV-1 Transcript In The Absence Of Tat Pathway (106005); DNA Repair Pathway (105837); Disease Pathway (530764); Dual Incision Reaction In TC-NER Pathway (105892); Epstein-Barr Virus Infection Pathway (585562); Epstein-Barr Virus Infection Pathway (587115); Eukaryotic Transcription Initiation Pathway (198917); Formation Of HIV-1 Elongation Complex Containing HIV-1 Tat Pathway (106004); Formation Of HIV-1 Elongation Complex In The Absence Of HIV-1 Tat Pathway (161052); Formation Of RNA Pol II Elongation Complex Pathway (105950)

This gene encodes the largest subunit of RNA polymerase II, the polymerase responsible for synthesizing messenger RNA in eukaryotes. The product of this gene contains a carboxy terminal domain composed of heptapeptide repeats that are essential for polymerase activity. These repeats contain serine and threonine residues that are phosphorylated in actively transcribing RNA polymerase. In addition, this subunit, in combination with several other polymerase subunits, forms the DNA binding domain of the polymerase, a groove in which the DNA template is transcribed into RNA. [provided by RefSeq, Jul 2008]

DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. Largest and catalytic component of RNA polymerase II which synthesizes mRNA precursors and many functional non-coding RNAs. Forms the polymerase active center together with the second largest subunit. Pol II is the central component of the basal RNA polymerase II transcription machinery. It is composed of mobile elements that move relative to each other. RPB1 is part of the core element with the central large cleft, the clamp element that moves to open and close the cleft and the jaws that are thought to grab the incoming DNA template. At the start of transcription, a single-stranded DNA template strand of the promoter is positioned within the central active site cleft of Pol II. A bridging helix emanates from RPB1 and crosses the cleft near the catalytic site and is thought to promote translocation of Pol II by acting as a ratchet that moves the RNA-DNA hybrid through the active site by switching from straight to bent conformations at each step of nucleotide addition. During transcription elongation, Pol II moves on the template as the transcript elongates. Elongation is influenced by the phosphorylation status of the C-terminal domain (CTD) of Pol II largest subunit (RPB1), which serves as a platform for assembly of factors that regulate transcription initiation, elongation, termination and mRNA processing. Regulation of gene expression levels depends on the balance between methylation and acetylation levels of tha CTD-lysines (). Initiation or early elongation steps of transcription of growth-factors-induced immediate early genes are regulated by the acetylation status of the CTD (PubMed:24207025). Methylation and dimethylation have a repressive effect on target genes expression ().

0.1 mg

280 USD